- Oops!Something went wrong.Please try again later.
Global Blood Therapeutics, Inc. GBT was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $37.65 –$62.90 in the past one-month time frame, witnessed a sharp increase yesterday.
The company has seen nine negative estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So, make sure to keep an eye on this stock going forward, to see if this recent move higher can last.
Global Blood Therapeutics currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
Global Blood Therapeutics, Inc. Price
Global Blood Therapeutics, Inc. price | Global Blood Therapeutics, Inc. Quote
Investors interested in the Medical - Biomedical and Genetics industry may consider Abeona Therapeutics Inc ABEO, which has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot stocks we're targeting >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Global Blood Therapeutics, Inc. (GBT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research